Matrix metalloproteinase 9 activity in urine of patients at risk for premature delivery

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 2, 1999, Pages 387-388

  Agrez, Michael ^a   Gu, Xinhua ^a   Giles, Warwick ^a,b  

^a School of Biomedical Sciences and Pharmacy   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Matrix metalloproteinase 9; Premature labor; Urine test

Indexed keywords

GELATINASE B;

CLINICAL ARTICLE; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; PATHOGENESIS; PREMATURE LABOR; PRIORITY JOURNAL; RISK ASSESSMENT; URINALYSIS;

EID: 0032823895     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70566-1     Document Type: Conference Paper

References (2)

1. 1. Vadillo-Ortega F, Hernandez A, Gonzales-Avila G, Bermejo L, Iwata K, Strauss JF III. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rapture of membranes. Am J Obstet Gynecol 1996;174:1371-6.
2. 2. Lukes AS, Thorp JM Jr, Eucker B, Pahel-Short L. Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. Am J Obstet Gynecol 1997;176:639-41.